BR112021023487A2 - Moléculas de ligação anti-tdp-43 e usos das mesmas - Google Patents
Moléculas de ligação anti-tdp-43 e usos das mesmasInfo
- Publication number
- BR112021023487A2 BR112021023487A2 BR112021023487A BR112021023487A BR112021023487A2 BR 112021023487 A2 BR112021023487 A2 BR 112021023487A2 BR 112021023487 A BR112021023487 A BR 112021023487A BR 112021023487 A BR112021023487 A BR 112021023487A BR 112021023487 A2 BR112021023487 A2 BR 112021023487A2
- Authority
- BR
- Brazil
- Prior art keywords
- tdp
- disease
- binding molecules
- present
- encephalopathy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2878—Muscular dystrophy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19176314 | 2019-05-23 | ||
| EP19195916 | 2019-09-06 | ||
| EP19207839 | 2019-11-07 | ||
| EP20161060 | 2020-03-04 | ||
| PCT/EP2020/064335 WO2020234473A1 (en) | 2019-05-23 | 2020-05-22 | Anti-tdp-43 binding molecules and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021023487A2 true BR112021023487A2 (pt) | 2022-02-08 |
Family
ID=70779783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021023487A BR112021023487A2 (pt) | 2019-05-23 | 2020-05-22 | Moléculas de ligação anti-tdp-43 e usos das mesmas |
Country Status (14)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112920264B (zh) * | 2021-02-08 | 2022-07-05 | 武汉大学 | Tdp-43蛋白的o-糖基化突变体及其应用 |
| WO2022174036A2 (en) * | 2021-02-11 | 2022-08-18 | Mayo Foundation For Medical Education And Research | Methods and materials for treating tdp-43 proteinopathies |
| CA3231484A1 (en) | 2021-10-01 | 2023-04-06 | Qinwen Mao | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
| AU2023221539A1 (en) | 2022-02-16 | 2024-08-22 | Ac Immune Sa | Humanized anti-tdp-43 binding molecules and uses thereof |
| IL316153A (en) | 2022-04-08 | 2024-12-01 | Ac Immune Sa | Anti-tdp-43 binding molecules |
| EP4389215A1 (en) * | 2022-12-20 | 2024-06-26 | Consejo Superior De Investigaciones Científicas | Chemically modified tdp-43 derived polypeptides and uses thereof |
| WO2024184494A1 (en) | 2023-03-08 | 2024-09-12 | Ac Immune Sa | Anti-tdp-43 binding molecules and uses thereof |
| KR102859015B1 (ko) * | 2023-07-20 | 2025-09-12 | 충북대학교 산학협력단 | cAbl에 의한 TDP43의 특이적 인산화 분석을 통한 신경퇴행성 질환을 진단하는 방법 및 이를 이용한 신경퇴행성 질환의 치료제 스크리닝 방법 |
| CN117126269B (zh) * | 2023-10-25 | 2024-02-13 | 首都儿科研究所 | 一种1型人博卡病毒型别特异性抗体及其应用 |
| WO2025134068A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Antibody drug conjugates targeting proteinopathies, and uses thereof |
| WO2025186332A1 (en) | 2024-03-05 | 2025-09-12 | Ac Immune Sa | Vectorized anti-tdp-43 antibodies |
| WO2026013218A1 (en) | 2024-07-10 | 2026-01-15 | Ac Immune Sa | Anti-tdp-43 vectors, binding molecules and uses thereof |
| WO2026132413A1 (en) | 2024-12-20 | 2026-06-25 | Bioarctic Ab | Antibody against tdp-43 |
| EP4781999A1 (en) * | 2025-01-24 | 2026-07-29 | Brainever | Engrailed protein for use in the treatment of tdp-43 proteinopathies |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US5688511A (en) | 1991-11-05 | 1997-11-18 | Board Of Regents, The University Of Texas System | Cellular protein TDP-43 and regulation of HIV-1 gene expression |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| FR2707189B1 (fr) | 1993-07-09 | 1995-10-13 | Gradient Ass | Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé. |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| IL154751A0 (en) | 2000-08-03 | 2003-10-31 | Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals | |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
| CA2543360A1 (en) | 2003-10-24 | 2005-05-06 | Joost A. Kolkman | Ldl receptor class a and egf domain monomers and multimers |
| HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| WO2008151055A1 (en) * | 2007-06-01 | 2008-12-11 | Mayo Foundation For Medical Education And Research | Diagnosing neurodegenerative diseases |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| EP2632434B1 (en) | 2010-10-26 | 2025-08-20 | AC Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| CA2853412C (en) * | 2011-10-28 | 2021-05-04 | University Of Zurich | Tdp-43 specific binding molecules |
| EP2825197B1 (en) | 2012-03-16 | 2018-06-06 | Covagen AG | Novel binding molecules with antitumoral activity |
| PT3334761T (pt) * | 2015-08-13 | 2023-08-17 | Univ New York | Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias |
| JP7761373B2 (ja) | 2017-05-30 | 2025-10-28 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | Tdp-43のrna認識モチーフ1(rrm1)中のエピトープ、およびそれらに対するミスフォールディング選択的抗体 |
-
2020
- 2020-05-22 CN CN202080038441.4A patent/CN114008073B/zh active Active
- 2020-05-22 EP EP20727297.2A patent/EP3972692A1/en active Pending
- 2020-05-22 US US17/613,444 patent/US12600766B2/en active Active
- 2020-05-22 PH PH1/2021/552938A patent/PH12021552938A1/en unknown
- 2020-05-22 KR KR1020217040767A patent/KR20220012270A/ko not_active Ceased
- 2020-05-22 SG SG11202112453TA patent/SG11202112453TA/en unknown
- 2020-05-22 CA CA3137882A patent/CA3137882A1/en active Pending
- 2020-05-22 WO PCT/EP2020/064335 patent/WO2020234473A1/en not_active Ceased
- 2020-05-22 MX MX2021014274A patent/MX2021014274A/es unknown
- 2020-05-22 BR BR112021023487A patent/BR112021023487A2/pt unknown
- 2020-05-22 TW TW109117264A patent/TW202110879A/zh unknown
- 2020-05-22 CN CN202510979312.XA patent/CN120943956A/zh active Pending
- 2020-05-22 JP JP2021569353A patent/JP2022533432A/ja active Pending
-
2021
- 2021-11-16 CL CL2021003027A patent/CL2021003027A1/es unknown
- 2021-11-22 IL IL288314A patent/IL288314A/en unknown
-
2024
- 2024-07-15 CL CL2024002125A patent/CL2024002125A1/es unknown
-
2025
- 2025-03-25 JP JP2025050500A patent/JP2025094219A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220315648A1 (en) | 2022-10-06 |
| CN120943956A (zh) | 2025-11-14 |
| EP3972692A1 (en) | 2022-03-30 |
| CN114008073A (zh) | 2022-02-01 |
| CL2024002125A1 (es) | 2024-12-20 |
| TW202110879A (zh) | 2021-03-16 |
| KR20220012270A (ko) | 2022-02-03 |
| IL288314A (en) | 2022-01-01 |
| MX2021014274A (es) | 2022-01-06 |
| CA3137882A1 (en) | 2020-11-26 |
| CL2021003027A1 (es) | 2022-06-24 |
| SG11202112453TA (en) | 2021-12-30 |
| JP2025094219A (ja) | 2025-06-24 |
| PH12021552938A1 (en) | 2022-07-25 |
| WO2020234473A1 (en) | 2020-11-26 |
| CN114008073B (zh) | 2025-08-12 |
| JP2022533432A (ja) | 2022-07-22 |
| AU2020278907A1 (en) | 2022-01-20 |
| US12600766B2 (en) | 2026-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014274A (es) | Moleculas de union anti-tdp-43 y usos de las mismas. | |
| CL2024002383A1 (es) | Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas. | |
| SA520412379B1 (ar) | جزيئات رابطة مختلة الطي لبروتين ربط الحمض النووي دي أوكسي ريبوزي ذي الاستجابة التشابكية 43 كيلو دالتون | |
| Varghese et al. | Chitotriosidase-a putative biomarker for sporadic amyotrophic lateral sclerosis | |
| Zhao et al. | Microbiome-generated amyloid and potential impact on amyloidogenesis in Alzheimer’s disease (AD) | |
| Yang et al. | IL-17A promotes the neuroinflammation and cognitive function in sevoflurane anesthetized aged rats via activation of NF-κB signaling pathway | |
| BRPI0821658B8 (pt) | anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos | |
| MX2021012608A (es) | Nuevas moleculas para terapia y diagnostico. | |
| Srivastava et al. | Inflammatory response of microglia to prions is controlled by sialylation of PrPSc | |
| Fraga et al. | Ketamine alters behavior and decreases BDNF levels in the rat brain as a function of time after drug administration | |
| BR112022000719A2 (pt) | Anticorpo anti-tau ou um fragmento de ligação ao antígeno do mesmo, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do anticorpo anti-tau ou fragmento de ligação ao antígeno do mesmo, hibridoma, composição farmacêutica, composição para diagnosticar uma doença neurológica degenerativa, kit, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo e método para prevenir ou tratar uma doença neurológica degenerativa | |
| BR112021016398A2 (pt) | Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer | |
| Qin et al. | Lipopolysaccharide preconditioning induces an anti-inflammatory phenotype in BV2 microglia | |
| BR112022024195A2 (pt) | Anticorpos anti-tgfss e usos terapêuticos dos mesmos | |
| Gold et al. | Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia | |
| BR112022015387A2 (pt) | Proteínas actriib variantes e usos das mesmas | |
| Folsom et al. | Protein expression of targets of the FMRP regulon is altered in brains of subjects with schizophrenia and mood disorders | |
| Gião et al. | Neuroprotection in early stages of Alzheimer’s disease is promoted by transthyretin angiogenic properties | |
| BR112022026341A2 (pt) | Anticorpos e métodos para o tratamento de doenças associadas à claudina | |
| BR112022026279A2 (pt) | Métodos de tratamento de alergia usando anticorpos anti-bet v 1 | |
| BR112021018688A2 (pt) | Composição para prevenir ou tratar doença cerebral e do sistema nervoso | |
| BR112022026999A2 (pt) | Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas | |
| Xiao et al. | Re-infection of the prion from the scrapie-infected cell line SMB-S15 in three strains of mice, CD1, C57BL/6 and Balb/c | |
| Watzlawik et al. | Polysialic acid as an antigen for monoclonal antibody HI gM12 to treat multiple sclerosis and other neurodegenerative disorders | |
| MX2025003560A (es) | Nuevos compuestos para el diagnostico de las proteinopatias por proteina de union al acido desoxirribonucleico (adn) de respuesta transactiva de 43 kilodalton (tdp-43) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |